Iovance Biotherapeutics Shares Rise After Receiving Canadian Approval for Skin Cancer Treatment

Dow Jones

Aug 19

By Connor Hart

Shares of Iovance Biotherapeutics climbed after the company's treatment for certain types of skin cancer received market authorization in Canada.

The stock rose 20% to $3 in premarket trading Tuesday. Through Monday's close, shares have lost more than three-quarters of their value in the past year.

The biotechnology company said late Monday that Health Canada issued a Notice of Compliance with Conditions for its treatment, Amtagvi, for adult patients with unresectable or metastatic melanoma that has progressed on or after at least one prior systemic therapy.

"This approval in Canada is our first marketing authorization outside the U.S. and marks a significant step forward for Iovance as we prepare to introduce Amtagvi in countries with a high prevalence of advanced melanoma and address substantial unmet needs in solid tumor cancers," interim Chief Executive Frederick Vogt said.

He added that the company plans to authorize its first Canadian treatment center in the coming months, as it continues to advance its strategy for Amtagvi in additional markets.

Health Canada's approval was granted based on safety and efficacy results from a recent Phase 2 study.

Write to Connor Hart at connor.hart@wsj.com

(END) Dow Jones Newswires

August 19, 2025 06:40 ET (10:40 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2560983281"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2560983281\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2560983281?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-19 18:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2560983281","market":"hk","top_or_hot":-1,"title":"Iovance Biotherapeutics Shares Rise After Receiving Canadian Approval for Skin Cancer Treatment","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Connor Hart \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/IOVA\">Iovance Biotherapeutics</a> climbed after the company's treatment for certain types of skin cancer received market authorization in Canada. \n</p>\n<p>\n  The stock rose 20% to $3 in premarket trading Tuesday. Through Monday's close, shares have lost more than three-quarters of their value in the past year. \n</p>\n<p>\n  The biotechnology company said late Monday that Health Canada issued a Notice of Compliance with Conditions for its treatment, Amtagvi, for adult patients with unresectable or metastatic melanoma that has progressed on or after at least one prior systemic therapy. \n</p>\n<p>\n  \"This approval in Canada is our first marketing authorization outside the U.S. and marks a significant step forward for Iovance as we prepare to introduce Amtagvi in countries with a high prevalence of advanced melanoma and address substantial unmet needs in solid tumor cancers,\" interim Chief Executive Frederick Vogt said. \n</p>\n<p>\n  He added that the company plans to authorize its first Canadian treatment center in the coming months, as it continues to advance its strategy for Amtagvi in additional markets. \n</p>\n<p>\n  Health Canada's approval was granted based on safety and efficacy results from a recent Phase 2 study. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  August 19, 2025 06:40 ET (10:40 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Iovance Biotherapeutics Shares Rise After Receiving Canadian Approval for Skin Cancer Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIovance Biotherapeutics Shares Rise After Receiving Canadian Approval for Skin Cancer Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-08-19 18:40</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Connor Hart \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/IOVA\">Iovance Biotherapeutics</a> climbed after the company's treatment for certain types of skin cancer received market authorization in Canada. \n</p>\n<p>\n  The stock rose 20% to $3 in premarket trading Tuesday. Through Monday's close, shares have lost more than three-quarters of their value in the past year. \n</p>\n<p>\n  The biotechnology company said late Monday that Health Canada issued a Notice of Compliance with Conditions for its treatment, Amtagvi, for adult patients with unresectable or metastatic melanoma that has progressed on or after at least one prior systemic therapy. \n</p>\n<p>\n  \"This approval in Canada is our first marketing authorization outside the U.S. and marks a significant step forward for Iovance as we prepare to introduce Amtagvi in countries with a high prevalence of advanced melanoma and address substantial unmet needs in solid tumor cancers,\" interim Chief Executive Frederick Vogt said. \n</p>\n<p>\n  He added that the company plans to authorize its first Canadian treatment center in the coming months, as it continues to advance its strategy for Amtagvi in additional markets. \n</p>\n<p>\n  Health Canada's approval was granted based on safety and efficacy results from a recent Phase 2 study. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  August 19, 2025 06:40 ET (10:40 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IOVA","symbol_name":"Iovance Biotherapeutics, Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2560983281","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2560983281","pubTimestamp":1755600000,"columns":[{"name":"Product Release","id":31,"label_key":"productRelease"}],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Iovance Biotherapeutics climbed after the company's treatment for certain types of skin cancer received market authorization in Canada.The stock rose 20% to $3 in premarket trading Tuesday. Through Monday's close, shares have lost more than three-quarters of their value in the past year.The biotechnology company said late Monday that Health Canada issued a Notice of Compliance with Conditions for its treatment, Amtagvi, for adult patients with unresectable or metastatic melanoma that has progressed on or after at least one prior systemic therapy.\"This approval in Canada is our first marketing authorization outside the U.S. and marks a significant step forward for Iovance as we prepare to introduce Amtagvi in countries with a high prevalence of advanced melanoma and address substantial unmet needs in solid tumor cancers,\" interim Chief Executive Frederick Vogt said.He added that the company plans to authorize its first Canadian treatment center in the coming months, as it cont","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IOVA":"Iovance Biotherapeutics, Inc.","BK4139":"生物科技"},"translate_title":"Iovance Biotherapeutics获得加拿大批准皮肤癌治疗后股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IOVA":0.9},"content_text":"By Connor Hart \n\n\n \n\n\n  Shares of Iovance Biotherapeutics climbed after the company's treatment for certain types of skin cancer received market authorization in Canada. \n\n\n  The stock rose 20% to $3 in premarket trading Tuesday. Through Monday's close, shares have lost more than three-quarters of their value in the past year. \n\n\n  The biotechnology company said late Monday that Health Canada issued a Notice of Compliance with Conditions for its treatment, Amtagvi, for adult patients with unresectable or metastatic melanoma that has progressed on or after at least one prior systemic therapy. \n\n\n  \"This approval in Canada is our first marketing authorization outside the U.S. and marks a significant step forward for Iovance as we prepare to introduce Amtagvi in countries with a high prevalence of advanced melanoma and address substantial unmet needs in solid tumor cancers,\" interim Chief Executive Frederick Vogt said. \n\n\n  He added that the company plans to authorize its first Canadian treatment center in the coming months, as it continues to advance its strategy for Amtagvi in additional markets. \n\n\n  Health Canada's approval was granted based on safety and efficacy results from a recent Phase 2 study. \n\n\n \n\n\n  Write to Connor Hart at connor.hart@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  August 19, 2025 06:40 ET (10:40 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}